Agendia Announces New Data from I-SPY 2 Showcasing Ability of New Signature ImPrintTN to Predict Immunotherapy Response in Patients with Triple Negative Breast Cancer

IRVINE, Calif. & AMSTERDAM–(BUSINESS WIRE)–Agendia®, Inc. today announced new data from the I-SPY 2 trial showcasing its ImPrint signature for patients with triple negative (TN) breast cancer, shared by I-SPY 2 researchers in an oral presentation at the 14th European Breast Cancer Conference in Milan, Italy. Agendia has been in…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks